Amgen Patents Beat Sandoz Validity Check In Biosimilar Fight
A New Jersey federal judge Friday rejected Sandoz Inc.'s attempt to invalidate two patents covering Amgen subsidiary Immunex Corp.'s blockbuster immunosuppressant Enbrel, stalling Sandoz's aim to launch a biosimilar version of...To view the full article, register now.
Already a subscriber? Click here to view full article